Genentech’s influenza treatment Xofluza (baloxavir marboxil) was granted approval by the U.S. Food and Drug Administration for use in people 12 years and older, making it the first single-dose post-exposure prophylaxis strategy approved by the regulatory agency.
If you are not happy with the results below please do another search
50 search results for:
Using blood plasma from Covid-19 survivors to treat patients with severe pneumonia caused by the novel coronavirus showed little benefit, according to data released from a clinical trial in Argentina.
U.S. officials plan to release 6.4 million Covid-19 vaccine doses nationwide in an initial distribution after the first one is cleared by regulators for emergency use.
Health and wellness advertising agency AbelsonTaylor hired Scott Moers as senior director of business development.
To support the long-term goals of Novartis, the Swiss pharma giant is initiating a share-buyback program of up to $2.5 billion that is expected to be carried out over the next few months.
Two months after stepping down from the role of chief executive officer of Legend Biotech, Fangliang “Frank” Zhang was arrested for smuggling genetic resources from the People’s Republic of China.
Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics that harnesses the properties of gold nanocrystals.
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.
U.S. Surgeon General Jerome Adams pleaded with Americans to grasp “the severity of the moment” and remain vigilant against the coronavirus pandemic, as record hospitalizations pushed healthcare professionals to the brink.
Join TLD Group Advisor and Senior Consultant Dr. Kent Bottles in a webinar on December 3rd that will discuss American Healthcare in 2021: What Should Providers, Patients, & Citizens Expect?